For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the arrival of Tafamidis and the formulated version represents a true change. These innovative therapies preserve the transthyretin protein, slowing its damaging build-up and alleviating the impact of the disease . Patients are now experiencing … Read More